ImmuPharma (LON: IMM) is a United Kingdom domiciled clinical stage therapeutics and Biotechnology company that has interests in the Research and development of novel therapeutics compounds as well as manufacturing of various drugs based on these compounds which are of immense value in the treatment of several critical life threatening ailments.
Headquartered in London the company also licences out its new and innovative therapies for critical diseases which are showcased as novel and featured by the company to serve the high unmet medical demand and also has low development and marketing costs. The company draws heavily from the Centre National de la Recherche Scientifique (National Centre for Scientific Research) (CNRS) for their dynamic research in the field of new compound discovery.
In its portfolio the company, currently has only one drug called Lupuzor™ useful for the treatment of Lupus and is in its late-stage clinical trial, with other potential applications for Auto-immune diseases, Oncology and Ophthalmology, as well as secondary applications for Metabolism and Diabetes.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.